Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 19:10:956141.
doi: 10.3389/fped.2022.956141. eCollection 2022.

Postnatal probiotic supplementation can prevent and optimize treatment of childhood asthma and atopic disorders: A systematic review of randomized controlled trials

Samuel N Uwaezuoke  1   2 , Adaeze C Ayuk  1   2 , Joy N Eze  1   2 , Chioma L Odimegwu  1   2 , Chibuzo O Ndiokwelu  1 , Ikenna C Eze  3   4
Affiliations

Postnatal probiotic supplementation can prevent and optimize treatment of childhood asthma and atopic disorders: A systematic review of randomized controlled trials

Samuel N Uwaezuoke et al. Front Pediatr. .

Abstract

Background: Although several randomized controlled trials (RCTs) published over the past 5 years show that prenatal or postnatal probiotics may prevent or optimize the treatment of childhood asthma and atopic disorders, findings from the systematic reviews and meta-analyses of these studies appear inconsistent. More recent RCTs have focused on postnatal probiotics, and linked specific probiotic strains to better disease outcomes.

Objective: This systematic review aimed to determine if postnatal probiotics are as effective as prenatal probiotics in preventing or treating childhood asthma and atopic disorders.

Methods: We searched the PubMed, Medline, Google Scholar, and EMBASE databases for RCTs published within the past 5 years (from 2017 to 2022). We included only full-text RCTs on human subjects published in or translated into the English language. We retrieved relevant data items with a preconceived data-extraction form and assessed the methodological quality of the selected RCTs using the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials. We qualitatively synthesized the retrieved data to determine any significant differences in study endpoints of the probiotic and placebo groups.

Results: A total of 1,320 participants (688 and 632 in the probiotic and placebo groups) from six RCTs were investigated. One RCT showed that early Lactobacillus rhamnosus GG (LGG) led to a reduction in the cumulative incidence rate of asthma. Another study demonstrated that mixed strains of Lactobacillus paracasei and Lactobacillus fermentum could support clinical improvement in children with asthma while one trial reported a significant reduction in the frequency of asthma exacerbations using a mixture of Ligilactobacillus salivarius and Bifidobacterium breve. Three trials showed that a combination of LGG and Bifidobacterium animalis subsp lactis, Lactobacillus rhamnosus alone, and a probiotic mixture of Lactobacillus ŁOCK strains improved clinical outcomes in children with atopic dermatitis and cow-milk protein allergy.

Conclusions: Postnatal strain-specific probiotics (in single or mixed forms) are beneficial in preventing and treating atopic dermatitis and other allergies. Similarly, specific strains are more effective in preventing asthma or improving asthma outcomes. We recommend more interventional studies to establish the most useful probiotic strain in these allergic diseases.

Keywords: atopic disease; childhood asthma; gastrointestinal microbiota; prevention; probiotics; therapeutics.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Algorithm for inclusion of randomized controlled trials on the use of probiotics in childhood asthma and atopic disorders.
Figure 2
Figure 2
Risk-of-bias assessment of the randomized controlled trials using the Cochrane Collaboration's tool.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bierbaum S, Heinzmann A. The genetics of bronchial asthma in children. Respir Med. (2007) 101:1369–75. 10.1016/j.rmed.2007.01.018 - DOI - PubMed
    1. Jameson JL, Longo DL. Precision medicine - personalized, problematic, and promising. N Engl J Med. (2015) 372:2229–34. 10.1056/NEJMsb1503104 - DOI - PubMed
    1. Chung KF. Precision medicine in asthma: linking phenotypes to targeted treatments. Curr Opin Pulm Med. (2018) 24:4–10. 10.1097/MCP.0000000000000434 - DOI - PubMed
    1. Stiemsma LT, Turvey SE. Asthma and the microbiome: defining the critical window in early life. Allergy Asthma Clin Immunol. (2017) 13:3. 10.1186/s13223-016-0173-6 - DOI - PMC - PubMed
    1. Plunkett CH, Nagler CR. The influence of the microbiome on allergic sensitization to food. Immunol. (2017) 198:581–9. 10.4049/jimmunol.1601266 - DOI - PMC - PubMed

Publication types